TGF-β1-deficient mice subjected to chronic subpressor doses of Ang II showed no significant cardiac hypertrophy or fibrosis [67], which suggests that strategies to block TGF-β signaling may be useful for treating fibrogenic cardiac remodeling. The gene discussed is TGFB1; the disease is cardiac hypertrophy.